Thymoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Thymoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Pembrolizumab and Lenvatinib for Patients with Pre-Treated Thymic Carcinoma and B3-Thymoma https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-lenvatinib-for-patients-with-pre-treated-thymic-carcinoma-and-b3-thymoma/ Wed, 29 Apr 2026 14:25:31 +0000 https://clinicaltrials.eu/trial/study-on-pembrolizumab-and-lenvatinib-for-patients-with-pre-treated-thymic-carcinoma-and-b3-thymoma/ This clinical trial is focused on studying the effectiveness and safety of a combination treatment for patients with a type of cancer called thymic carcinoma and a subtype known as B3-thymoma. These are rare cancers that occur in the thymus, a small organ in the upper chest. The treatment being tested includes two medications: pembrolizumab, also known by its code name MK-3475, and lenvatinib, known by its code name MK-7902. Pembrolizumab is given as an infusion, which means it is administered directly into the bloodstream through a vein, while lenvatinib is taken orally in capsule form.

The purpose of this study is to evaluate how well this combination of medications works in patients who have already received other treatments for their cancer. The study will look at how long patients can live without their disease getting worse over a period of five months. Participants will receive the treatment for up to 24 months, and their health will be monitored regularly to assess the treatment’s effects and any side effects they may experience.

Throughout the study, researchers will also gather information on how the cancer responds to the treatment, including any reduction in tumor size and overall survival rates. The safety of the treatment will be closely monitored to ensure it is well-tolerated by patients. This study aims to provide valuable insights into the potential benefits of using pembrolizumab and lenvatinib together for treating thymic carcinoma and B3-thymoma.

]]> Study on Calcium Folinate to Reduce Pemetrexed Side Effects in Patients with Non-Small Cell Lung Cancer, Mesothelioma, or Thymoma https://clinicaltrials.eu/trial/study-on-calcium-folinate-to-reduce-pemetrexed-side-effects-in-patients-with-non-small-cell-lung-cancer-mesothelioma-or-thymoma/ Wed, 29 Apr 2026 14:24:57 +0000 https://clinicaltrials.eu/trial/study-on-calcium-folinate-to-reduce-pemetrexed-side-effects-in-patients-with-non-small-cell-lung-cancer-mesothelioma-or-thymoma/ This clinical trial is focused on studying the effects of a treatment for certain types of cancer, specifically Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, and Thymoma. The treatment being tested is called Rescuvolin, which contains the active substance calcium folinate. This medication is being used to see if it can help reduce side effects caused by another cancer treatment called pemetrexed.

The purpose of the study is to evaluate how well calcium folinate can prevent or lessen the side effects, particularly those affecting blood cells, when used alongside pemetrexed. Participants in the study will be randomly assigned to receive either the calcium folinate treatment or a placebo, in addition to their regular cancer treatment. The study will monitor the participants over a period of time to observe any changes in their health, especially focusing on blood cell counts and other potential side effects.

Throughout the study, participants will take the medication in the form of tablets, and their health will be closely monitored by healthcare professionals. The study aims to provide valuable information on whether calcium folinate can effectively reduce the side effects of pemetrexed, potentially improving the quality of life for patients undergoing treatment for these types of cancer.

]]>